A compound of formula including any tautomeric and stereochemically isomeric form thereof, wherein A 1, A 2, A 3 and A 4 each independently represent CH, CR a1, CR a2 or N; provided that when one or more of A 1, A 2, A 3 and A 4 represent a substituted carbon atom, at least one of said substituted carbon atoms represents CR a1, and provided that maximun three of A 1, A 2, A 3 and A 4 may represent CR a1 or CR a2; C1 is hydrogen or C 1-4 alkyl; C2 is hydrogen, C 1-4 alkyl, hydroxyl or C 1-4 alkoxy; or C1 and C2 are taken together to form a C 3-6 cycloalkyl together with the carbon atom to which they are attached; each R a1 independently is halo, C 1-6 alkyl, haloC 1-6 alkyl, cyano, -OR c, -N(R c) 2, -C(=O)-N(R c) 2, -S(=O)-C 1-6 alkyl, -S(=O) 2 -C 1-6 alkyl or C 3-6 cycloalkyl; each R a2 independently is C 1-6 alkyl, haloC 1-6 alkyl, halo, C 1-6 alkoxy, carboxyl, C 1-6 alkyloxycarbonyl, C 2-6 alkenyl, C 2-6 alkynyl, cyano, cyanoC 1-6 alkyl, hydroxyC 1-6 alkyl, -C(=O)-NH 2, -C(=O)-NH(C 1-4 alkyl), -C(=O)-N(C 1-4 alkyl) 2, or a 3 to 6 membered monocyclic saturated heterocyclyl containing at least one heteroatom selected from N, O or S; R c is hydrogen, C 1-4 alkyl or C 1-4 alkyloxyC 1-4 alkyl; R b is hydrogen, C 1-6 alkyl, haloC 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkyloxycarbonyl, C 2-6 alkenyl, C 2 6 alkynyl, cyanoC 1-6 alkyl, hydroxyC 1-6 alkyl, -C(=O)-NH 2, -C(=O)-NH(C 1-4 alkyl), -C(=O)-N(C 1-4 alkyl) 2, C 3-6 cycloalkyl, phenyl, a 3 to 6 membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O or S, or C 1-6 alkyl substituted with C 3-6 cycloalkyl or with phenyl or with a 3 to 6 membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O or S; B is a 3 to 12 membered carbocyclyl or a 3 to 12 membered heterocyclyl containing at least one heteroatom selected from N, O or S, wherein said carbocyclyl and heterocyclyl are each optionally being substituted with 1 to 5 R substituents; each R independently is C 1-6 alkyl, cyano, halo, C 1-6 alkoxy, haloC 1-6 alkoxy, hydroxyl, hydroxyC 1-6 alkyl, haloC 1-6 alkyl, oxo, -SO 2 -NH 2, -SO 2 -NH(C 1-4 alkyl), -SO 2 -N(C 1-4 alkyl) 2, -NH-C(=O)-C 2-6 alkenyl, -C(=O)-C 1-6 alkyl, -C(=O)-C 2-6 alkenyl, C 1-6 alkyl-O-C(=O)-, C 3-6 cycloalkyl, phenyl, or a 3 to 6 membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O or S; or a pharmaceutically acceptable salt thereof or a solvate thereof. A 1, A 2, A 3 and A 4 each independently represent CH, CR a1, CR a2 or N; provided that when one or more of A 1, A 2, A 3 and A 4 represent a substituted carbon atom, at least one of said substituted carbon atoms represents CR a1, and provided that maximun three of A 1, A 2, A 3 and A 4 may represent CR a1 or CR a2; C1 is hydrogen or C 1-4 alkyl; C2 is hydrogen, C 1-4 alkyl, hydroxyl or C 1-4 alkoxy; or C1 and C2 are taken together to form a C 3-6 cycloalkyl together with the carbon atom to which they are attached; each R a1 independently is halo, C 1-6 alkyl, haloC 1-6 alkyl, cyano, -OR c, -N(R c) 2, -C(=O)-N(R c) 2, -S(=O)-C 1-6 alkyl, -S(=O) 2 -C 1-6 alkyl or C 3-6 cycloalkyl; each R a2 independently is C 1-6 alkyl, haloC 1-6 alkyl, halo, C 1-6 alkoxy, carboxyl, C 1-6 alkyloxycarbonyl, C 2-6 alkenyl, C 2-6 alkynyl, cyano, cyanoC 1-6 alkyl, hydroxyC 1-6 alkyl, -C(=O)-NH 2, -C(=O)-NH(C 1-4 alkyl), -C(=O)-N(C 1-4 alkyl) 2, or a 3 to 6 membered monocyclic saturated heterocyclyl containing at least one heteroatom selected from N, O or S; R c is hydrogen, C 1-4 alkyl or C 1-4 alkyloxyC 1-4 alkyl; R b is hydrogen, C 1-6 alkyl, haloC 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkyloxycarbonyl, C 2-6 alkenyl, C 2 6 alkynyl, cyanoC 1-6 alkyl, hydroxyC 1-6 alkyl, -C(=O)-NH 2, -C(=O)-NH(C 1-4 alkyl), -C(=O)-N(C 1-4 alkyl) 2, C 3-6 cycloalkyl, phenyl, a 3 to 6 membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O or S, or C 1-6 alkyl substituted with C 3-6 cycloalkyl or with phenyl or with a 3 to 6 membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O or S; B is a 3 to 12 membered carbocyclyl or a 3 to 12 membered heterocyclyl containing at least one heteroatom selected from N, O or S, wherein said carbocyclyl and heterocyclyl are each optionally being substituted with 1 to 5 R substituents; each R independently is C 1-6 alkyl, cyano, halo, C 1-6 alkoxy, haloC 1-6 alkoxy, hydroxyl, hydroxyC 1-6 alkyl, haloC 1-6 alkyl, oxo, -SO 2 -NH 2, -SO 2 -NH(C 1-4 alkyl), -SO 2 -N(C 1-4 alkyl) 2, -NH-C(=O)-C 2-6 alkenyl, -C(=O)-C 1-6 alkyl, -C(=O)-C 2-6 alkenyl, C 1-6 alkyl-O-C(=O)-, C 3-6 cycloalkyl, phenyl, or a 3 to 6 membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O or S; or a pharmaceutically acceptable salt thereof or a solvate thereof.